Nektar Therapeutics's market cap is currently $195.53M. The company's EPS TTM is $-0.837; its P/E ratio is ―; Nektar Therapeutics is scheduled to report earnings on February 27, 2025, and the estimated EPS forecast is $-0.14. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 90.12M	$ 92.06M	$ 101.91M	$ 152.91M	$ 114.62M
Gross Profit	$ 53.48M	$ 70.42M	$ 77.01M	$ 133.44M	$ 93.24M
Operating Income	$ -137.43M	$ -240.24M	$ -446.10M	$ -379.92M	$ -440.04M
EBITDA	$ -243.11M	$ -323.87M	$ -462.97M	$ -394.33M	$ -382.70M
Net Income	$ -276.06M	$ -368.20M	$ -523.84M	$ -444.44M	$ -440.67M
Balance Sheet
Cash & Short-Term Investments	$ 303.62M	$ 504.98M	$ 733.96M	$ 1.06B	$ 1.32B
Total Assets	$ 398.03M	$ 710.60M	$ 1.12B	$ 1.54B	$ 1.98B
Total Debt	$ 117.78M	$ 131.50M	$ 143.18M	$ 150.29M	$ 403.94M
Net Debt	$ 82.50M	$ 43.27M	$ 117.96M	$ -48.67M	$ 307.58M
Total Liabilities	$ 267.05M	$ 343.96M	$ 437.68M	$ 461.47M	$ 571.97M
Stockholders' Equity	$ 130.99M	$ 366.64M	$ 679.51M	$ 1.08B	$ 1.41B
Cash Flow
Free Cash Flow	$ -193.47M	$ -309.68M	$ -427.65M	$ -320.55M	$ -354.97M
Operating Cash Flow	$ -192.61M	$ -304.01M	$ -412.66M	$ -313.29M	$ -328.68M
Investing Cash Flow	$ 139.56M	$ 365.83M	$ 202.78M	$ 496.21M	$ 206.89M
Financing Cash Flow	$ 30.00K	$ 1.51M	$ 36.24M	$ -80.35M	$ 23.36M

Currency in USD

Nektar Therapeutics Earnings and Revenue History

Income Statement >

Nektar Therapeutics Debt to Assets

Balance Sheet >

Nektar Therapeutics Cash Flow

Cash Flow >

Nektar Therapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing